KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biocryst Pharmaceuticals (BCRX) Short term Debt (2023 - 2025)

Biocryst Pharmaceuticals' Short term Debt history spans 3 years, with the latest figure at $38.5 million for Q4 2025.

  • For Q4 2025, Short term Debt rose 17.69% year-over-year to $38.5 million; the TTM value through Dec 2025 reached $38.5 million, up 17.69%, while the annual FY2025 figure was $38.5 million, 17.69% up from the prior year.
  • Short term Debt reached $38.5 million in Q4 2025 per BCRX's latest filing, up from $37.7 million in the prior quarter.
  • In the past five years, Short term Debt ranged from a high of $38.5 million in Q4 2025 to a low of $23.6 million in Q4 2023.
  • Average Short term Debt over 3 years is $32.3 million, with a median of $33.0 million recorded in 2024.
  • Peak YoY movement for Short term Debt: skyrocketed 38.66% in 2024, then increased 14.2% in 2025.
  • A 3-year view of Short term Debt shows it stood at $23.6 million in 2023, then surged by 38.66% to $32.7 million in 2024, then increased by 17.69% to $38.5 million in 2025.
  • Per Business Quant, the three most recent readings for BCRX's Short term Debt are $38.5 million (Q4 2025), $37.7 million (Q3 2025), and $35.7 million (Q2 2025).